Company: NYXH
Filing Date: 2025-08-11
Form Type: 6-K
Source: 0001104659-25-075831
Chunk: 5

Company: Nyxoah SA
Filing Date: 2025-08-11
Form: 6-K
Chunk 5
---
 from infringement claims
could increase and this could exhaust our financial and management resources. Further, during the course of any litigation, we may make
announcements regarding the results of hearings and motions, and other interim developments. If securities analysts and investors regard
these announcements as negative, the market price of our common stock may decline. Any of the foregoing could prevent us from competing
effectively and could have an adverse effect on our business, financial condition, and operating results.

Additionally, competitors and other third parties
may infringe or otherwise violate our issued patents or other intellectual property or the patents or other intellectual property of our
licensors. In addition, our patents or the patents of our licensors may become involved in inventorship or priority disputes. Our pending
patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a
patent issues from such applications. To counter infringement or other unauthorized use, we may be required to file infringement claims,
which can be expensive and time-consuming. Our ability to enforce patent rights also depends on our ability to detect infringement. It
may be difficult to detect infringers who do not advertise the components or methods that are used in connection with their products and
services. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor’s or potential competitor’s
product or service. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging
that we infringe their patents or that our patents are invalid or unenforceable. In a patent infringement proceeding, a court may decide
that a patent of ours is invalid or unenforceable, in whole or in part, construe the patent’s claims narrowly or refuse to stop
the other party from using the technology at issue on the grounds that our patents do not cover the technology. An adverse result in any
litigation proceeding could put one or more of our owned or licensed patents at risk of being invalidated, held unenforceable or interpreted
narrowly. We may find it impractical or undesirable to enforce our intellectual property against some third parties.

Our future financial performance depends on the commercial acceptance of the Genio system in target markets.

The Genio system is currently
our only commercial product, which we currently market in certain European countries. On August 8, 2025, we announced that the U.S. Food
and Drug Administration, or FDA, granted approval of the Genio® system for a subset of patients with moderate